This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
35
Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
University of Maryland, Greenebaum Cancer Center
Baltimore, Maryland, United States
University of Utah Health Sciences Center, Department of Medicine, Division of Hematology, Utah Blood and Marrow Transplant and Myeloma Program
Salt Lake City, Utah, United States
AZ Sint-Jan
Bruges, Belgium
Ghent University Hospital
Ghent, Belgium
Safety assessed as Adverse Events, ECG, vital signs and clinical laboratory tests
Time frame: four weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rigshospitalet
Copenhagen, Denmark
Karolinska University Hospital
Huddinge, Sweden
Hematology Clinic Cancer Division, Skåne University Hospital
Lund, Sweden